首页> Haemophilia : the official journal of the World Federation of Hemophilia> Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A.

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A.

导出原文传递

翻译打印收藏纠错

第一作者： Elena,Santagostino

第一单位： Foundation IRCCS Ca' Granda, Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

作者： Elena,Santagostino ^[1] ; Shadan,Lalezari ^[2] ; Mark T,Reding ^[3] ; Jonathan,Ducore ^[4] ; Heng Joo,Ng ^[5] ; Lone H,Poulsen ^[6] ; Lisa A,Michaels ^[7] ; Camila,Linardi ^[7]

作者单位： Foundation IRCCS Ca' Granda, Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy. ^[1] Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.;Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel. ^[2] Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA. ^[3] Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA. ^[4] Department of Haematology, Singapore General Hospital, Singapore. ^[5] The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark. ^[6] Bayer, Whippany, NJ, USA. ^[7]

关键词 PEGylation clinical outcome clinical trials extended half-life factor VIII haemophilia A minor surgery

医学主题词因子Ⅷ(Factor VIII);半衰期(Half-Life);血友病A(Hemophilia A);人类(Humans);聚乙烯二醇类(Polyethylene Glycols);治疗结果(Treatment Outcome)

DOI 10.1111/hae.14319

PMID 33939226

发布时间 2021-09-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交